Table 4.

Proportions of children with lipid abnormalities 9, 20 and 31 months after randomization to either remain on ritonavir-boosted lopinavir (control group) or switch to NVP-based therapy (switch group)

	Control group	Switch group
	n/N (%)	n/N (%)	p value*
9 months post-randomization
Total cholesterol
Borderline high 170-199 mg/dL	14/93 (15.1)	20/88 (22.7)
High ≥ 200 mg/dL	13/93 (14.0)	11/88 (12.5)	>0.10
Low density lipoprotein
Borderline high 110-129 mg/dL	8/93 (8.6)	8/87 (9.2)
High ≥ 130 mg/dL	8/93 (8.6)	9/87 (10.3)	>0.10
High density lipoprotein
Low < 40 mg/dL	43/93 (46.2)	22/87 (25.3)	0.004
Triglycerides
High >150 mg/dl	35/93 (37.6)	25/87 (28.7)	>0.10
20 months post-randomization
Total cholesterol
Borderline high 170-199 mg/dL	27/79 (34.2)	18/74 (24.3)
High ≥ 200 mg/dL	16/79 (20.3)	8/74 (10.8)	0.05
Low density lipoprotein
Borderline high 110-129 mg/dL	15/72 (20.8)	9/72 (12.5)
High ≥ 130 mg/dL	7/72 (9.7)	4/72 (5.6)	>0.10
High density lipoprotein
Low < 40 mg/dL	29/73 (39.7)	17/73 (23.3)	0.03
Triglycerides
High >150 mg/dl	22/70 (31.4)	16/73 (21.9)	>0.10
31 months post-randomization
Total cholesterol
Borderline high 170-199 mg/dL	28/67 (41.8)	12/55 (21.8)
High ≥ 200 mg/dL	11/67 (16.4)	7/55 (12.7)	0.03
Low density lipoprotein
Borderline high 110-129 mg/dL	8/67 (11.9)	10/58 (17.2)
High ≥ 130 mg/dL	8/67 (11.9)	5/58 (8.6)	>0.10
High density lipoprotein
Low < 40 mg/dL	27/67 (40.3)	11/58 (19.0)	0.01
Triglycerides
High >150 mg/dl	24/68 (35.3)	6/57 (10.5)	0.001

^*Groups are compared using chi-square tests